Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Paper mills’ are contaminating the world’s scholarly output with fake papers that hinder research. Lifesaving biomedical fields are especially hard hit.

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

The Shetland Way, by Marianne Brown, tells a tale of wind power – and local-outsider venom – that could be coming to your corner of England ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Authoritative and well-researched, Chemically Imbalanced documents the overinflation of antidepressant efficacy, where the ...

Simply put, Mixbook remains the best service of the five we tested for making photo books. While some competitors excelled at one thing or another, Mixbook does just about everything right. Its ...

Shares of Eli Lilly and Co. fell more than 7% in midday trading Tuesday after the Indianapolis company announced its fourth quarter revenue would fall short of expectations. Lilly said its U.S ...

Indianapolis: Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small molecule precision oncology therapies, have announced a definitive agreement for ...

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

"2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 with strong financial and operational performance," continued Ricks. "Sales of Mounjaro and ...